This co-dependency benefits the tumor, but it also implies that therapies that target one population may also reduce the immunosuppressive activity of the other cell population (i.e., the application of anti-PD-L1 or anti-CTLA-4 inhibitors in the clinical setting). The gene discussed is CD274; the disease is neoplasm.